This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Salubris (Chengdu) Biotech Co., Ltd., Salubris Biotherapeutics, Inc.. Active years: 2021-2023.
Company Filing History:
2 out of 2 
2 out of 2 Years Active: 2021-2023
Title: Yiran Wu: Innovator in Recombinant Fusion Proteins
Introduction
Yiran Wu is a prominent inventor based in Chengdu, China. He has made significant contributions to the field of biotherapeutics, particularly in the development of recombinant fusion proteins. With a total of 2 patents, his work focuses on innovative methods for treating various diseases.
Latest Patents
Yiran Wu's latest patents include a groundbreaking invention related to human neuregulin-1 (NRG-1) recombinant fusion protein compositions. This invention involves a recombinant fusion protein that comprises a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone. The method outlined in the patent describes how to treat a disease or condition in a subject in need by administering a therapeutically effective amount of the recombinant fusion protein or a pharmaceutical composition containing it.
Career Highlights
Throughout his career, Yiran Wu has worked with notable companies in the biotherapeutics sector, including Salubris Biotherapeutics, Inc. and Salubris (Chengdu) Biotech Co., Ltd. His expertise in recombinant proteins has positioned him as a key player in the development of innovative treatments.
Collaborations
Yiran Wu has collaborated with esteemed colleagues such as John H Li and Shengwei Li. These partnerships have further enhanced his research and development efforts in the field of biotherapeutics.
Conclusion
Yiran Wu's contributions to the field of recombinant fusion proteins demonstrate his commitment to advancing medical science. His innovative patents and collaborations highlight his role as a leading inventor in biotherapeutics.